Halimeh Hassanpour | Plant Cell Biology | Best Academic Researcher Award

Dr. Halimeh Hassanpour | Plant Cell Biology | Best Academic Researcher Award

Dr. Halimeh Hassanpour, Aerospace Research Institute, Ministry of Science Research and Technology, Tehran, Iran, Iran

Dr. Halimeh Hassanpour is a distinguished plant physiologist and researcher at the Aerospace Research Institute, affiliated with the Ministry of Science, Research and Technology, Iran. With a Ph.D. in Plant Biology and Physiology from Kharazmi University (2012), she has emerged as a pioneer in the interdisciplinary field of plant space biology. Her research uniquely integrates plant physiology, biotechnology, and environmental stress responses, with a special focus on microgravity and spaceflight conditions. Dr. Hassanpour has led numerous industrial and academic projects involving medicinal plants, algae, and nanoparticles, producing over 40 peer-reviewed articles in SCI/Scopus-indexed journals. She is the author of a notable book on plant responses to gravity and has significantly contributed to space-oriented biological research in Iran. Her Google Scholar citation count exceeds 780, demonstrating the relevance and impact of her work globally. Dr. Hassanpour stands as a leader in advancing sustainable solutions for agriculture and pharmaceuticals in extreme environments.

Publication Profile: 

Google Scholar

Orcid

Strength of the Awards:

  1. Interdisciplinary Expertise: Dr. Hassanpour has successfully bridged plant physiology with space biology—an emerging and globally significant research domain.

  2. High Impact Research: With 781 citations on Google Scholar and publications in SCI/Scopus-indexed journals, her research has gained wide academic recognition.

  3. Innovative Focus Areas:

    • Stress physiology in medicinal plants

    • Plant responses to microgravity, magnetic fields, and nanoparticles

    • Secondary metabolite enhancement in in vitro and space-simulated environments

  4. Applied Industrial Collaborations: She has led industry-driven projects with measurable outcomes, such as optimizing astaxanthin production from algae and Capsicum growth under controlled lighting.

  5. Authorship of a Specialized Book: Her 2019 book on gravity and plant response mechanisms reflects a leadership role in space-biology research.

  6. Prolific Output: Over 20 peer-reviewed publications, with strong citation counts (e.g., 80, 69, 63), and active contributions to journals like BMC Plant Biology, Scientific Reports, and Journal of Space Science and Technology.

Areas for Improvement:

  1. Global Outreach: While her work is innovative, participation in international collaborations and space biology networks would enhance visibility.

  2. Commercialization Strategy: More focus on translational research or tech transfer (e.g., patents, startup ventures) could extend the impact beyond academic circles.

  3. Patent Portfolio: Although her work has application potential, published patents or filings would further validate industrial relevance.

Education:

Dr. Hassanpour earned her Ph.D. in Plant Biology and Physiology from Kharazmi University of Iran in 2012. Her doctoral research focused on physiological and biochemical responses of medicinal plants to abiotic stresses such as salinity, drought, and magnetic fields. Prior to her Ph.D., she obtained a Master’s and Bachelor’s degree in Plant Sciences, with a focus on the mechanisms of plant stress adaptation. During her academic journey, she specialized in advanced plant tissue culture, molecular biology, enzymology, and stress physiology techniques. Her education provided the foundation for her pioneering work in plant space biology—especially how plants respond to microgravity, clinorotation, and magnetic stimuli. Her interdisciplinary academic background has uniquely positioned her to bridge the gap between plant sciences and aerospace research, making her an expert in developing stress-resilient plants for space and extreme Earth environments.

Experience:

Dr. Halimeh Hassanpour currently serves as a senior researcher and faculty member at the Aerospace Research Institute, Ministry of Science, Research, and Technology in Iran. With over a decade of professional experience, she has worked extensively on national and industrial projects, particularly in plant tissue culture, algae biotechnology, and plant responses to environmental stressors. She collaborates with pharmaceutical and agricultural industries, including Karandishan Company and Rezvan Molay Garden Company, optimizing plant production under controlled and stress-simulated environments. Her expertise includes designing bioreactor systems, evaluating oxidative stress biomarkers, and studying gene expression under unique space-simulated conditions. She has also authored a scientific book and serves as a consultant on space biology for plant-based life support systems. Her multi-sectoral experience blends research excellence with real-world applications in agriculture, pharmaceuticals, and space sciences, showcasing her as an influential contributor to both academia and industry.

Research Focus:

Dr. Hassanpour’s research lies at the intersection of plant space biology, stress physiology, and biotechnology. She investigates how medicinal and edible plants adapt to abiotic stress conditions such as low atmospheric pressure, magnetic fields, microgravity, and nanoparticles, mimicking space or harsh terrestrial environments. A key theme of her work involves optimizing plant and algae cultures for pharmaceutical compound production, like astaxanthin from Haematococcus algae or physalins from Physalis alkekengi. She employs tools such as in vitro tissue culture, clinorotation, spectroscopy, and gene expression analysis to study the modulation of antioxidant defense mechanisms, nitric oxide pathways, and DNA methylation under stress. Her findings contribute to the development of resilient plant systems for space missions, controlled-environment agriculture (CEA), and phytopharmaceutical applications. With broad applications in both the space and health industries, her research bridges fundamental biology with innovative technologies aimed at sustainability and health improvement.

Publications Top Notes:

  1. 🌶️ Red light induced seed germination and seedling growth in Capsicum frutescens – BMC Plant Biology, 2025

  2. 🧫 Effect of low atmospheric pressure on Dunaliella salina – Journal of Space Science and Technology, 2024

  3. 🍒 Optimized Physalis alkekengi callus culture for nitric oxide and antioxidants – Scientific Reports, 2024

  4. 🧪 ROS regulation in Dunaliella salina via fulvic acid – Journal of Applied Phycology, 2024

  5. 🧲 Cell suspension culture of Physalis under static magnetic field – Protoplasma, 2024

  6. 🌿 Hyoscyamus niger under clinorotation: alkaloids & gene expression – Protoplasma, 2024

  7. 🌊 SiO2 nanoparticles in Spirulina platensis: enzyme & metabolite response – Plant Process and Function, 2024

  8. 🚀 Simulated microgravity enhancing secondary metabolism in Physalis – Acta Physiologiae Plantarum, 2023

  9. 🧲 Overview of magnetic field effects on plant physiology – Iranian Journal of Plant Physiology, 2023

  10. ⚙️ Iron oxide nanoparticles and antioxidant response in Physalis – Russian Journal of Plant Physiology, 2023

Conclusion:

Dr. Halimeh Hassanpour is a highly suitable candidate for the Best Academic Researcher Award. Her original contributions in space plant biology, environmental stress physiology, and plant biotechnology have placed her among the leaders in a niche but rapidly growing field. With her continued output, interdisciplinary integration, and innovative research direction, she exemplifies the qualities of a world-class academic researcher deserving of recognition.

Amr Hanbali | Therapeutic use of Cellular therapy in cancer treatment | Best Researcher Award

Assoc. Prof. Dr. Amr Hanbali | Therapeutic use of Cellular therapy in cancer treatment | Best Researcher Award

Assoc. Prof. Dr. Amr Hanbali | King Faisal Specialist Hospital & Research Center | Saudi Arabia

Dr. Amr AlHanbali is a dual-certified Hematology and Oncology consultant with over 18 years of experience in malignant and benign hematological conditions. Based at King Faisal Specialist Hospital & Research Center in Riyadh, Saudi Arabia, he specializes in hematologic malignancies and stem cell transplantation. Dr. AlHanbali previously served as a senior staff physician and Associate Fellowship Program Director at Henry Ford Health System in Detroit, Michigan. Recognized for his academic involvement, he holds teaching appointments at Wayne State University and Alfaisal University. Known for his dedication to clinical mentorship, he has trained numerous medical students, residents, and fellows. He is actively involved in research and is a member of several prestigious medical organizations including the American Society of Hematology and American Society of Clinical Oncology. With expertise ranging from bone marrow procedures to managing complex hematologic disorders, Dr. AlHanbali is a respected leader in the field of hematology and stem cell transplantation.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contribution

    • Over 17 peer-reviewed publications, including impactful case reports, national guidelines, and original research in hematology, oncology, and stem cell transplantation.

    • Active contributor to national guidelines on multiple myeloma, reflecting leadership in shaping national healthcare standards in KSA.

  2. Dual Academic and Clinical Roles

    • Combines academic excellence (as faculty at Wayne State University and Alfaisal University) with hands-on clinical expertise at a premier institution (King Faisal Specialist Hospital & Research Center).

  3. Innovative Focus in Hematology and Transplantation

    • Research into underexplored areas such as hepatitis B reactivation post-rituximab, genetic donor match outcomes, and therapies for AL amyloidosis.

  4. International Exposure and Leadership

    • Experience across the U.S. and Saudi Arabia, influencing programs in both systems.

    • Played a key role in training and selecting future hematology-oncology fellows in the U.S.

  5. Mentorship and Capacity Building

    • Mentored numerous trainees, enhancing research culture among younger clinicians.

Areas for Improvement:

  1. Higher Impact Publications Needed

    • While the volume and variety of research are commendable, more publications in top-tier journals (NEJM, Lancet, Blood, JCO) could boost citation impact and visibility.

  2. Research Grants and Collaborative Trials

    • Pursuing multicenter studies, international collaborations, or industry-sponsored clinical trials would further elevate his profile and expand research funding sources.

  3. Technological Innovation/Patents

    • Exploring biotech innovation, AI in diagnostics, or cellular therapy patents could position him among the top medical innovators.

Education:

Dr. Amr AlHanbali completed his Bachelor of Medicine and Surgery from the University of Jordan in 1999. He pursued medical training in the United States, starting with an internal medicine residency (2001–2004) at Henry Ford Health System, Detroit. He continued his specialization with a fellowship in Hematology and Oncology (2004–2007) at the same institution. During his training, he also undertook elective rotations in Pediatric Cardiology and Gastroenterology at the University of Texas Medical Branch, Galveston, further enriching his academic exposure. He is certified by the American Board of Internal Medicine in Internal Medicine (2004), Hematology (2007), and Oncology (2007). Dr. AlHanbali holds academic titles as a Clinical Assistant Professor at Wayne State University, Detroit, and Adjunct Associate Professor at Alfaisal University, Riyadh. His educational background reflects a strong foundation in internal medicine, with a deep focus on hematology and oncology, further supported by teaching and research excellence.

Experience:

Dr. AlHanbali’s clinical career spans over 18 years, currently serving as Hematology and Stem Cell Transplant Consultant at King Faisal Specialist Hospital & Research Center in Riyadh since 2013. Prior to this, he held multiple leadership roles at Henry Ford Health System, Detroit, including Senior Staff Physician and Associate Fellowship Program Director (2007–2013). His medical expertise covers the diagnosis and treatment of a wide range of hematologic malignancies such as leukemia, lymphoma, multiple myeloma, and myeloproliferative disorders. Dr. AlHanbali also has extensive experience in stem cell transplantation, intrathecal chemotherapy, and bone marrow biopsy. He has been instrumental in resident selection and curriculum development for fellowship programs in hematology and oncology. His work bridges clinical excellence with academic mentorship, guiding numerous trainees and junior physicians. In addition to patient care, he is involved in clinical guideline development and research, particularly in the field of multiple myeloma and transplant outcomes.

Research Focus:

Dr. Amr AlHanbali’s research is centered on hematologic malignancies, particularly multiple myeloma, lymphoma, leukemia, and stem cell transplantation. His work explores novel therapeutic approaches, transplant outcomes, disease progression, and treatment-related complications. He has contributed significantly to research on hepatitis B reactivation, chemotherapy-induced toxicities, and the protective role of comorbidities like diabetes in cancer metastasis. As an active member of the Saudi Myeloma Working Group, he has co-authored national guidelines for both newly diagnosed and relapsed/refractory multiple myeloma. His studies also examine health disparities in cancer care, including outcomes among African American populations and the impact of familial genetics in donor matches. With over a dozen peer-reviewed publications and case reports in high-impact journals, Dr. AlHanbali continues to push forward understanding in clinical hematology and oncology. He combines bedside insights with academic rigor to shape evidence-based practice and improve treatment outcomes in cancer and transplant medicine.

Publications Top Notes:

  1.  Mediastinal Hematoma With SVC Syndrome From A Central Venous Catheter Insertion – CHEST, 2003

  2.  Diabetes Has Protective Effect Against Metastasis in Non-Small Cell Lung Cancer – Arch Intern Med, 2007

  3.  Delayed Hepatitis B Viral Replication Post-Rituximab & Fludarabine in Waldenstrom Macroglobulinemia – Am J Hematol, 2007

  4.  Acute Pancreatitis Induced by Adult Precursor B-cell ALL – South Med J, 2007

  5.  Hypersensitivity Reaction of Mylotarg with Platelet Transfusion – Am J Health Syst Pharm, 2007

  6.  Incidence of Hepatitis B Reactivation after Rituximab Therapy – Am J Hematol, 2009

  7. Outcomes After Auto-SCT in African Americans with Multiple Myeloma – Bone Marrow Transplant, 2009

  8.  HER-2 Status May Change in Recurrent Breast Cancer – Cancer Research, 2009

  9.  Compartment Syndrome as Presentation of Chronic Myelogenous Leukemia – J Gen Intern Med, 2010

  10.  Use of Insulin and its Effect on Survival in NSCLC – J Clin Oncol, 2009

Conclusion:

Dr. Amr AlHanbali demonstrates a stellar blend of clinical expertise, research productivity, academic mentorship, and leadership in hematology and oncology. His research contributions have practical implications in areas such as multiple myeloma, leukemia, transplant immunology, and chemotherapy safety.

He is highly deserving of recognition and stands out as a top contender for a Best Researcher Award, particularly in the categories of clinical research excellence, translational hematology, and medical education integration with research.

Balasubramanian Murugesan | Cell Surface Receptors | Best Researcher Award

Dr. Balasubramanian Murugesan | Cell Surface Receptors | Best Researcher Award

Dr. Balasubramanian Murugesan, K.S.Rangasamy College of Arts and Science (Autonomous), Tamilnadu State, India, India

Dr. M. Balasubramanian, M.Phil., Ph.D., SET, is an accomplished Indian researcher and educator specializing in microbiology, enterobacterial infections, molecular biology, and lichen-based bioprospective studies. Born on May 17, 1984, he brings over 14 years of cumulative experience in academia and industry. His expertise spans molecular simulations and therapeutic compound discovery from natural sources, particularly lichens. With a strong foundation in life sciences and teaching biotechnology at both UG and PG levels, Dr. Balasubramanian is committed to nurturing scientific inquiry and translational research. He is actively involved in advanced drug discovery using in silico techniques and has published widely in SCOPUS and Web of Science-indexed journals. His interdisciplinary work, particularly in evaluating the biomedical potential of foliose lichens, has earned him professional recognition. As a life member of various academic societies, he continues to contribute to global biosciences with impactful teaching, research, and innovation.

Publication Profile: 

Orcid

Strengths for the Award:

  1. Multidisciplinary Expertise
    Dr. Balasubramanian’s research spans across core areas of modern biosciences, including microbiology, molecular biology, bioinformatics, phytochemistry, and computational simulations. His work contributes directly to combating infectious diseases and cancer therapeutics.

  2. Outstanding Research Contributions
    With over 11 peer-reviewed publications, many in SCOPUS, Web of Science, and SCI-indexed journals, he has explored novel bioactive compounds from lichens and plants. His recent in silico study on usnic acid as a potential anti-cancer agent showcases the translational relevance of his research.

  3. Academic & Industrial Experience
    Accumulating 14+ years of combined teaching and industrial experience, he has shaped student careers while applying his knowledge in practical settings — a rare blend of academic insight and applied research.

  4. Award-Winning Track Record & Recognitions

    • Ranked 8th in B.Sc. Microbiology by Periyar University

    • Completed NITTTR training on Biotechnology & Biomedical Engineering

    • Holder of a Certificate of Excellence, recognizing his research quality and productivity

  5. Membership in Professional Bodies
    Active life member in five national and international organizations, such as the Indian Microbiology Society, Indian Lichenological Society, and the International Association of Engineers, reflecting his professional network and scientific credibility.

Areas for Improvement:

  1. Grant Acquisition and Funding Visibility
    There is limited data on participation in externally funded research projects. Securing national/international research grants could further elevate the impact and scope of his research.

  2. International Collaborations
    While his research is impactful, collaboration with global institutions could enhance visibility and provide broader application and funding opportunities.

  3. Technology Transfer and Patents
    Patenting and product commercialization of the bioactive compounds explored (like lichen-derived anti-cancer agents) would strengthen the applied dimension of his research.

Educational Qualifications:

Dr. Balasubramanian’s educational background showcases academic distinction across microbiology and biotechnology. He earned his B.Sc. in Microbiology from Periyar University, securing the 8th rank in March 2004. Following this, he pursued an M.Phil. in Biotechnology from Periyar University in 2008, completing it with First Class (68%). His academic journey culminated with a Ph.D. in Biotechnology (Animal Biotechnology specialization) from Bharathiar University, Coimbatore, in 2015, where his research focused on in vitro, in silico, and in vivo biomedical applications of foliose lichens. Additionally, he qualified the State Eligibility Test (SET) conducted by Mother Teresa Women’s University, Kodaikanal, in 2016. His solid academic credentials are supported by his deep-rooted interest in microbial pathogenesis, pharmacological studies, and computational biology. Dr. Balasubramanian’s education has laid a firm foundation for his prolific research and impactful academic career.

Professional Experience:

With 13 years and 6 months of teaching experience and 1 year and 2 months in industry, Dr. Balasubramanian has a rich, multidisciplinary background. He began as a Lecturer at Vivekanandha College for Women, Tiruchengode (2007–2008), teaching undergraduate and postgraduate biotechnology students. He later served as an Assistant Professor at SSM College of Arts and Science, Komarapalayam (2009–2010), handling core UG biotechnology subjects. His cumulative experience of over 14 years blends academic excellence with industry-relevant applications. His teaching is research-oriented, focusing on molecular biology, drug development, and microbiology. Apart from classroom instruction, he has supervised numerous student projects, engaged in scientific collaborations, and developed educational resources. Dr. Balasubramanian’s career reflects a commitment to fostering scientific curiosity and research skills among students, while also contributing significantly to applied biomedical research in academia.

Awards and Honors:

Dr. M. Balasubramanian has earned multiple recognitions for his academic and research excellence. He achieved the 8th Rank in B.Sc. Microbiology from Periyar University (2004), marking early academic distinction. He completed a short-term training course on “Biotechnology and Biomedical Engineering” at NITTTR, Chandigarh in 2008, conducted by the Ministry of HRD, Government of India. He has been honored with a Certificate of Excellence for his impactful scientific contributions, reflecting peer recognition for his ongoing commitment to biotechnology. He is also a Life Member of respected organizations including the Indian Lichenological Society, International Association of Engineers (UK), Indian Microbiology Society, and others. These memberships affirm his standing in the global scientific community. Dr. Balasubramanian’s recognition stems from his interdisciplinary research in natural compound therapeutics, molecular dynamics, and microbial pharmacology, qualifying him as a top candidate for research awards in his field.

Research Focus:

Dr. Balasubramanian’s research is focused on the biomedical potential of natural compounds, especially foliose lichens, using in vitro, in vivo, and in silico methodologies. His Ph.D. work involved extensive analysis of Sticta weigelii, Dermatocarpon vellereum, and Heterodermia boryi for their pharmacological efficacy. He explores molecular docking and dynamic simulations to assess ligand interactions with cancer and microbial proteins—particularly relevant in oncology and antimicrobial therapy. He is also deeply engaged in microbial diversity studies, bioprospection, and green synthesis of bioactive compounds from plants and lichens. His interdisciplinary methods integrate microbiology, pharmacology, computational biology, and plant chemistry, producing findings that have appeared in SCOPUS and Web of Science journals. Recent studies include targeting cervical cancer proteins using lichen-derived molecules. His translational research approach aims to bridge traditional medicine with modern biotechnology, contributing to novel drug development and therapeutic strategies in healthcare.

Publications Top Notes:

  1. 🧪 Salivary analysis of reative oxygen species in OSF and OSCC patients – Int. J. Biosci. (2012)

  2. 🧬 Effect of α-tocopherol on salivary ROS in oral submucous fibrosis – Ann. Clin. Biochem. (2012)

  3. 🌳 Genetic diversity in Acacia constricta and Acacia farnesiana – Int. J. Med. Res. (2012)

  4. 🌿 Phytochemical screening and antibacterial activity of Nyctanthes arbor-tristis – J. Chem. Pharm. Res. (2012)

  5. 🦠 Antimycobacterial activity of foliose lichens – Int. J. Pharm. Sci. Res. (2014)

  6. 🌱 Antioxidant properties of foliose lichens – J. Chem. Pharm. Res. (2014)

  7. 💊 Pharmacological study of Flavoparmelia caperata for analgesic use – IOSR J. Pharm. (2018)

  8. 🧫 In vitro and in vivo study on foliose lichens for biomedical uses – Int. Interdisciplinary Res. J. (2018)

  9. 🌾 Secondary metabolites and anticancer activity of Azadirachta indica – J. Appl. Sci. Comp. (2019)

  10. 📚 Review of pharmaceutical uses of Heliotropium genus – Eur. J. Pharm. Med. Res. (2020)

 

Conclusion:

Dr. M. Balasubramanian’s extensive work in the discovery of natural bioactive compounds, especially his interdisciplinary research into cancer therapeutics using lichens and computational biology, represents an exemplary model of innovation in life sciences. His strong academic foundation, consistent publishing record, and societal relevance of research make him highly deserving of the Best Researcher Award. With further international collaboration and grant-funded projects, he is poised to become a thought leader in biomedical biotechnology.

Kwaghgba Elijah Gbabe | Cell Structure Analysis | Best Researcher Award

Dr. Kwaghgba Elijah Gbabe | Cell Structure Analysis | Best Researcher Award

Dr. Kwaghgba Elijah Gbabe | Nigerian Stored Products Research Institute | Nigeria

Engr. Dr. Kwaghgba Elijah Gbabe is a seasoned Senior Research Officer at the Nigerian Stored Products Research Institute (NSPRI), Ilorin, Nigeria. With over nine years of progressive research experience, he specializes in food processing, postharvest technology, and agricultural nanotechnology. He is a trailblazer in developing electrospun hexanal nanofiber matrices aimed at extending the shelf-life of fruits such as bananas, mangoes, and tomatoes. His research integrates innovative preservation technologies to enhance food quality and sustainability. A COREN-certified engineer and postgraduate fellow, Dr. Gbabe has collaborated internationally, notably with the Centre for Agricultural Nanotechnology in India. With extensive publications and conference contributions, he is an advocate of research-driven food security and sustainable packaging. He brings a multidisciplinary edge to the evolving field of agricultural innovation, focusing on reducing postharvest losses and increasing storage efficiency in sub-Saharan Africa.

Publication Profile:

Google Scholar

Strengths for the Award:

  1. Innovative Research in Agricultural Nanotechnology

    • Pioneered the development of electrospun hexanal nanofiber matrices for fruit shelf-life extension — an emerging and impactful technology in food preservation.

  2. Strong Publication Record 

    • Over a dozen peer-reviewed journal articles and conference papers published across international and national platforms with DOIs, indicating high-quality scholarly contribution.

  3. Hands-On International Collaboration 

    • Completed a research internship at TNAU, India, and collaborated with renowned global experts like Prof. K.S. Subramanian in nanoscience.

  4. Multi-disciplinary Skills 

    • Expertise in advanced instrumentation (FTIR, GC-MS, SEM, TEM) and statistical tools (R, SPSS) shows broad technical competence.

  5. Real-world Application & Societal Impact 

    • Focuses on postharvest technologies to reduce food losses, enhance food safety, and support smallholder farmers and artisans.

  6. Leadership and Mentorship

    • Supervises junior staff, fabricators, and trainees, and contributes to capacity building through training workshops.

  7. Recognized Academic Achievement 

    • Recipient of the Benue State University Postgraduate Fellowship (2020–2025).

Areas for Improvement:

  1. Technology Commercialization and Patenting

    • While research output is strong, translating research into commercial products or patents could increase impact.

  2. Broader International Visibility

    • Participation in more international consortia or grants (e.g., EU Horizon, USAID, FAO) could elevate the global footprint.

  3. Expanded Multidisciplinary Outreach

    • Could integrate more with biotech and AI in agri-research, especially in smart packaging and AI-driven postharvest solutions.

Education:

Dr. Gbabe is currently pursuing his Ph.D. in Food Processing and Technology at Benue State University, Makurdi (2020–2025), with a research focus on developing electrospun hexanal nanofiber matrices for fruit preservation. He holds a Master of Engineering in Agricultural and Environmental Engineering from the University of Agriculture, Makurdi (2017–2019), where his thesis explored eco-building materials using rice husk and sawdust. His undergraduate and professional training background is further enhanced by a Certificate in Computer Appreciation (2010), an internship at the Centre for Agricultural Nanotechnology, TNAU, India (2023), and registration with COREN (2024). Dr. Gbabe is also a member of the Nigerian Institution of Agricultural Engineers (NIAE-M2207), demonstrating a strong foundation in both academic knowledge and regulatory standards in engineering and food technology. His educational pursuits reflect a consistent drive toward sustainability, innovation, and technological adaptation in agricultural systems.

Experience:

Dr. Gbabe serves as a Senior Research Officer at NSPRI since 2016, where he leads projects on postharvest technology, storage engineering, and food shelf-life enhancement. His duties span experimental design, research data analysis, technical report writing, equipment fabrication supervision, and stakeholder training. He has been instrumental in developing novel postharvest technologies and electrospun hexanal nanofiber matrices for fruit preservation. In 2023, he completed a research internship at the Centre for Agricultural Nanotechnology, TNAU, India, gaining hands-on experience in nanotoxicity, food nanotechnology, and biosafety. Dr. Gbabe is known for his interdisciplinary collaboration, capacity-building initiatives, and extensive field and lab-based research. He also coordinates training programs for artisans, farmers, and students. His rich professional journey is marked by impactful project execution, community-focused technology dissemination, and consistent contributions to national and international research publications.

Research Focus:

Dr. Gbabe’s research is centered on postharvest loss reduction, sustainable food preservation, and agricultural nanotechnology. He is pioneering the use of electrospun hexanal nanofiber matrices to extend the shelf-life of perishable fruits like bananas, mangoes, and tomatoes—a major advancement in food storage technology. His work addresses the chemical and biological challenges in postharvest handling, integrating advanced techniques such as FTIR, GC-MS, SEM, and TEM to monitor quality and degradation. He is also exploring green materials for packaging and eco-friendly building solutions using agricultural waste like rice husks and sawdust. His international collaboration with TNAU, India, expanded his research in nanotoxicity and food safety. With a focus on experimental design, interdisciplinary innovation, and practical application, Dr. Gbabe contributes to the development of scalable, cost-effective technologies tailored for African agricultural ecosystems. His goal is to enhance food security through intelligent preservation methods and sustainable postharvest engineering.

Publication Top Notes:

  1.  Effect of Hexanal Nano-fiber Matrix on Quality Parameters of Tomato Fruits during Storage

  2.  Development of Novel Hexanal Nano-fibre Matrix by Electrospinning for Shelf-life Extension of Mango Fruits

  3.  Implication of Different Storage Techniques on Physical Attributes of African Okra (Abelmoschus esculentus)

  4.  Maize Grains Milling Efficiency: A Performance Analysis of a Hammer Mill

  5.  Insecticidal and Toxicity Studies of Heliotropium Indicum Leaf Extracts for Stored Grain Pest Control

  6.  Commercial Utilization of Inert Atmosphere Silo for Maize Storage

  7.  Chemical and Physico-chemical Properties of OFSP Chips Dried Using Solar Dryers

  8.  Evaluation of the Use of Rice Husk in Producing Eco-Building Materials

  9.  Pros and Cons of AI Thermal Imaging in Postharvest Handling of Agricultural Products

  10.  Development of Hexanal Electrospun Nano-fiber Matrix for Banana Preservation

Conclusion:

Engr. Dr. Kwaghgba Elijah Gbabe is an exemplary researcher who combines scientific rigor, technological innovation, and practical application in the field of food systems and agricultural engineering. His pioneering work in nanotechnology, coupled with his leadership in postharvest technology, makes him exceptionally deserving of the Best Researcher Award.

Srinivas Ayyadevara | Cardiovascular and neurodegenerative disorders | Best Researcher Award

Prof. Dr. Srinivas Ayyadevara | Cardiovascular and neurodegenerative disorders | Best Researcher Award

Prof. Dr. Srinivas Ayyadevara, University of Arkansas for Medical Sciences and CAVHS (GRECC), United States

Dr. Srinivas Ayyadevara is a distinguished Research Health Scientist and Professor whose impactful work in aging, neurodegeneration, and cardiovascular research has spanned over two decades. Currently serving at the Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences (UAMS), Dr. Ayyadevara is known for his pioneering studies on protein aggregation, mitochondrial dysfunction, and cellular stress responses. His multidisciplinary background in biochemistry, genetics, and molecular biology has enabled him to address critical questions in age-related diseases, particularly Alzheimer’s disease. His career is marked by an exceptional publication record, strong federal research contributions, and a long-standing commitment to mentoring and collaboration. With a proven track record in translational science, Dr. Ayyadevara exemplifies the qualities sought in a top-tier biomedical researcher and continues to make significant contributions to the health and longevity of aging populations.

Publication Profile: 

Google Scholar

Strengths for the Award:

  1. Extensive Research Portfolio:
    Dr. Ayyadevara has a prolific track record of peer-reviewed publications across high-impact journals in fields of aging, neurodegeneration, cardiovascular biology, and molecular mechanisms of disease.

  2. Innovative Contributions:
    His studies have pioneered understanding of protein aggregation, mitochondrial dysfunction, autophagic failure, and pharmacological interventions for Alzheimer’s and age-related pathologies. His recent contributions using neural-network analysis and systems biology approaches are particularly cutting-edge.

  3. Multidisciplinary Expertise:
    With formal education in genetics, chemistry, biochemistry, and molecular biology, and research spanning model organisms to human data, Dr. Ayyadevara’s versatility is a hallmark of modern biomedical research excellence.

  4. Translational Impact:
    His work addresses major public health concerns (e.g., Alzheimer’s, heart disease, aging), with findings that could directly impact therapeutic strategies, particularly for aging populations and veterans.

  5. Longevity of Research Commitment:
    Over two decades of continuous research experience, including long-term federal service with the VA system, reflects sustained productivity and dedication.

  6. Collaborative Leadership:
    He co-authors with multidisciplinary teams, mentors junior scientists, and contributes to community-building within aging and biomedical research.

Areas for Improvement:

  1. Principal Investigator Leadership Visibility:
    While Dr. Ayyadevara contributes significantly to many studies, increased leadership as the sole or lead PI on large federal grants or multi-center collaborations would further highlight his independent research stature.

  2. Recognition and Awards:
    Despite an exceptional track record, public awards, keynote lectures, or national recognition (e.g., from NIH, VA, or gerontological societies) appear underreported. Greater visibility in these areas could bolster his profile.

  3. Patent/Technology Translation:
    The available information does not indicate patent filings or commercialization of findings. Highlighting translational milestones may strengthen his profile for broader impact assessments.

Education:

Dr. Srinivas Ayyadevara’s educational journey began in India, where he earned a B.Sc. (Hons) in Botany, Chemistry, and Biochemistry (1985) and an M.Sc. in Genetics (1987) from Osmania University. He later pursued an M.Sc. in Chemistry at Louisiana Tech University in the U.S. (1993), before completing his Ph.D. in Biochemistry and Molecular Biology at the University of Arkansas for Medical Sciences (1999). His diverse educational background reflects a robust foundation in life sciences, integrating classical genetics with modern molecular biology. This solid academic preparation has greatly informed his experimental approaches in biogerontology and neurodegeneration. His transition from plant and microbial studies to mammalian and human-focused research reflects a clear trajectory toward translational science aimed at combating aging and disease. This interdisciplinary and international academic training positions him well for leadership in cutting-edge biomedical research.

Experience:

Dr. Ayyadevara has over 25 years of biomedical research experience, including more than 17 years as a Research Health Scientist at the Central Arkansas Veterans Healthcare System. Since 2008, he has held this GS-13 level position, contributing to VA research in aging and neurodegeneration. As of July 2025, he serves as a Professor in the Department of Geriatrics at UAMS, following his role as an Associate Professor. His career includes hands-on lab leadership, collaboration with clinical investigators, and senior authorship of high-impact publications. He has led or co-led numerous translational studies involving Alzheimer’s disease, cardiovascular aging, proteomics, and mitochondrial function. Dr. Ayyadevara’s work frequently bridges basic science with clinical relevance, making tangible contributions to veteran health and public aging research. He is a trusted mentor and team leader whose experience spans model organisms, human tissue studies, and molecular interventions aimed at extending healthspan.

Research Focus:

Dr. Srinivas Ayyadevara’s research centers on understanding the molecular underpinnings of aging and age-associated diseases, with a particular emphasis on Alzheimer’s disease, cardiovascular aging, mitochondrial dysfunction, and protein aggregation. He employs model organisms like C. elegans, as well as human and mouse models, to study mechanisms of cellular stress, proteostasis, and genetic resilience to aging. A recurring theme in his work is the role of protein crosslinking and mitochondrial signaling in neurodegenerative and cardiac pathologies. His group is recognized for developing novel tools like the Leave-One-Out-Analysis (LOOA) to study protein interactions in aggregates and identifying actionable targets for drug development. Recently, he has investigated how common pharmaceuticals like ezetimibe and TDZD analogs reduce pathological aggregation. His research merges systems biology, proteomics, and pharmacological screening—offering promising therapeutic avenues for age-related diseases.

Publications Top Notes:

  1.  Mitochondria in aging and age-associated diseases – Mitochondrion, 2025

  2.  Altered protein homeostasis in cardiovascular diseases contributes to Alzheimer’s-like neuropathology – Basic Res Cardiol, 2025

  3.  Ezetimibe reduces Alzheimer’s risk by targeting 14-3-3G::Hexokinase interaction – Aging Biol, 2024

  4.  Model systems reveal pathways to reduce cryoprotectant toxicity – Cryobiology, 2024

  5.  LOOA: A web tool for protein interaction prediction in aggregation studies – Bioinformation, 2024

  6.  Neural-network analysis identifies drug targets in Alzheimer’s amyloid interactome – iScience, 2023

  7.  Small molecules rescue ApoE4-induced autophagy failure in Alzheimer’s disease – Commun Biol, 2024

  8.  Heart attack increases ER stress and aggregation in heart and brain – Mol Cell Biochem, 2023

  9.  TDZD analogs improve neurodegeneration models and extend lifespan in C. elegans – Pharmaceuticals, 2023

  10.  Proteomic analysis of ischemic heart and exosome modulation – Biochem Biophys Rep, 2023

Conclusion:

Dr. Srinivas Ayyadevara is highly suitable for the Best Researcher Award. His consistent, high-impact research over the years, especially in aging, neurodegeneration, and systems biology, combined with his commitment to veteran health and translational outcomes, makes him an outstanding candidate. With a few enhancements in national visibility and leadership designation, his already strong profile could rise to the top tier of internationally recognized researchers.

Shima Shafiee | Cell Structure Analysis | Best Researcher Award

Dr. Shima Shafiee | Cell Structure Analysis | Best Researcher Award

Dr. Shima Shafiee, Razi University, Iran

Shima Shafiee is an accomplished Iranian researcher specializing in computer systems architecture and bioinformatics, with a strong focus on machine learning applications in biological data analysis. She recently earned her Ph.D. in Computer Engineering from Razi University, where she focused on predictive modeling of protein-peptide binding interactions. Currently under consideration at the IDEL Lab, Shahid Bahonar University of Kerman, Shima has authored numerous national and international publications. With a rich background in algorithm optimization and artificial intelligence, her research stands at the intersection of computational biology, deep learning, and evolutionary algorithms. Shafiee’s work has contributed to the development of predictive tools in bioinformatics, such as DP-site and SPPPred, and she consistently ranks at the top of her academic cohort. Her ability to integrate traditional computer engineering concepts with advanced biological research makes her a notable candidate for the Best Researcher Award.

Publication Profile: 

Google Scholar

Strengths for the Award:

  1. Strong Academic Foundation
    Dr. Shafiee has a stellar academic record, graduating first in her Ph.D. class at Razi University with a CGPA of 3.77 and a thesis grade of 3.98, under the supervision of respected experts in computer engineering and bioinformatics.

  2. Innovative Interdisciplinary Research
    Her research bridges computer systems architecture, machine learning, and bioinformatics, with notable contributions to protein-peptide binding prediction, a critical domain in drug discovery and computational biology.

  3. High-Impact Publications
    She has published in IEEE/ACM Transactions, Applied Soft Computing, and Methods, reflecting both quality and visibility in international forums. Tools like SPPPred and DP-site demonstrate her practical impact in bioinformatics.

  4. Research Originality and Versatility
    Dr. Shafiee has developed hybrid models combining genetic programming, support vector machines, and deep learning, with practical tools and open-source contributions.

  5. Early Recognition and Outreach
    She has been active in academic dissemination since 2015, with selected papers in national and international conferences, showing early promise and consistency.

  6. Teaching and Mentorship
    Through her roles as a lecturer at multiple institutions, she has contributed to academic growth at the grassroots level.

Areas for Improvement:

  1. International Collaboration & Visibility
    While her publication quality is strong, Dr. Shafiee could expand her global visibility through collaborations with international research labs, EU Horizon, or NIH-funded projects.

  2. Post-Ph.D. Grant Applications
    She could benefit from applying for independent research grants or postdoctoral fellowships to lead projects that could shape the future of AI in biology.

  3. Open-Source Software and Data Availability
    While her models are impactful, increased accessibility via open-source repositories (e.g., GitHub) would boost reproducibility and encourage broader adoption.

  4. Industry Impact Metrics
    More emphasis on industry collaborations, patents, or application of models in clinical/biotech settings would enhance translational impact.

Education:

Shima Shafiee completed her Ph.D. in Computer Engineering (2016–2024) from Razi University, specializing in Computer Systems Architecture. Her dissertation titled “Application of learning-based models in predicting of protein-peptide binding interactions” earned her a thesis grade of 3.98/4.00 and an overall CGPA of 3.77. She worked under the guidance of Dr. Abdolhossein Fathi and Dr. Ghazaleh Taherzadeh, focusing on bioinformatics using deep learning, ensemble learning, and evolutionary algorithms. Prior to her Ph.D., she was ranked third in her Master’s program (2015). Shafiee’s educational background is rooted in computational problem-solving, algorithm development, and cross-disciplinary research involving biological data. Her consistent academic excellence and high-ranking performance culminated in her being recognized as the top Ph.D. student in 2025, a testament to her dedication and scholarly capabilities. Her education blends rigorous theory with innovative applied research, making her exceptionally well-prepared for high-impact contributions in academia and industry.

Experience:

Shima Shafiee’s experience spans both academic and applied computer engineering roles. She began her journey with an internship at Kimia Pardaz Pars Company (2013). Between 2015 and 2016, she served as a lecturer for computer fundamentals at Fajr High School and Al-Zahra Seminary School in Jiroft, where she taught introductory computer science to pre-university students. These experiences highlight her foundational teaching skills and outreach to educational institutions in her community. Her major academic contribution began during her Ph.D., where she collaborated with IDEL Lab and contributed to developing tools like SPPPred and DP-site, combining genetic programming, support vector machines, and deep learning to predict protein-peptide binding regions. Her experience uniquely blends educational outreach, algorithmic development, and publication-driven research in machine learning, optimization, and computational biology, reflecting her versatility and impact across the scientific and academic spectrum.

Awards & Honors:

Shima Shafiee has earned multiple distinctions recognizing her academic and research excellence. In 2015, she was named the third-place student in her Master’s program, demonstrating early academic excellence. Her continuous dedication to research and scholarship led her to be recognized as the first-place student in her Ph.D. program in 2025. One of her papers was selected at the 2nd International Congress of Electrical Engineering, Computer Science, and Information Technology (2015), highlighting the innovation and relevance of her early research in optimization algorithms. Her high publication output, including appearances in top-tier venues like IEEE/ACM Transactions on Computational Biology and Bioinformatics and Applied Soft Computing, reflects a consistent standard of excellence. These honors collectively showcase her as a standout figure in her field, with both academic and applied contributions acknowledged at national and international levels.

Research Focus:

Shima Shafiee’s research lies at the intersection of machine learning, bioinformatics, and computational systems engineering. Her primary focus is the prediction of protein-peptide binding interactions using intelligent algorithms such as genetic programming, ensemble models, and deep learning techniques. She has proposed several innovative hybrid models combining sequence-based and structure-based features to identify critical interaction residues. Her doctoral thesis and publications have led to the development of tools like SPPPred and DP-site, which aid in biological sequence analysis, with applications in drug discovery, protein function prediction, and biomedical engineering. Shafiee also has a strong background in optimization algorithms, especially particle swarm optimization (PSO), applied to computationally intensive problems like bin packing. Her ability to blend theoretical computing with practical biological data analysis makes her contributions valuable to both computational scientists and biologists, and positions her as a leading candidate for research recognition awards in AI and bioinformatics.

Publications Top Notes: 

  • 🧠 SPPPred: sequence-based protein-peptide binding residue prediction using genetic programming and ensemble learning (IEEE/ACM TCBBS, 2022)

  • 🔍 Prediction of protein–peptide-binding amino acid residues regions using machine learning algorithms (CSICC, 2021)

  • 🧬 Combination of genetic programming and SVM-based prediction of protein-peptide binding sites (Journal of Computing and Security, 2021)

  • 🧪 Prediction of protein–peptide binding residues using classification algorithms (IEEE Bioengineering Conf, 2020)

  • 🧠 A Review of the Uses of AI in Protein Research (Peptide Science Conf, 2019)

  • 🤖 DP-site: dual deep learning method for protein-peptide interaction site prediction (Methods, 2024)

  • 🧬 Protein-peptide interaction region prediction using generative sampling & ensemble DL (Applied Soft Computing, 2025)

  • 🧠 Comparing classification vs. segmentation predictors in protein-peptide interaction (CSICC, 2025)

  • 🧬 Leveraging structure-based and learning-based predictors in protein-peptide interaction (ICCKE, 2024)

  • 📘 Application of learning-based models in protein-peptide binding (Ph.D. Dissertation, 2024)

Conclusion:

Dr. Shima Shafiee is a highly suitable candidate for the Best Researcher Award based on her academic excellence, interdisciplinary research achievements, and consistent contributions to the fields of artificial intelligence and bioinformatics. Her ability to bridge computer science and biological challenges has resulted in meaningful and applicable solutions. She has displayed originality, depth, and foresight in her work, developing novel methods that align with modern computational biology trends.

Xinmei Zhang | Endometriosis | Best Researcher Award

Prof. Dr. Xinmei Zhang | Endometriosis | Best Researcher Award

Prof. Dr. Xinmei Zhang, Women’s Hospital, School of Medicine, Zhejiang University, China

Prof. Xinmei Zhang is the Chief Physician at the Women’s Hospital, School of Medicine, Zhejiang University, and a professor in the same institution. With over two decades of clinical and academic experience in gynecology, she has become a leading expert in the diagnosis and treatment of gynecological diseases, particularly endometriosis and adenomyosis. Her work integrates clinical excellence with cutting-edge research, focusing on women’s reproductive health, minimally invasive surgery, and gynecologic oncology. Prof. Zhang also holds several editorial roles in international journals and actively collaborates with institutions worldwide including MD Anderson Cancer Center (USA), Cochin Hospital (France), and Fudan University (Brazil). As an ambassador and key committee leader in multiple gynecological associations, she contributes significantly to shaping global standards in reproductive health. Her numerous publications and international recognition underscore her commitment to advancing women’s health through translational research and global collaboration.

Publication Profile: 

Orcid

Scopus

Strengths for the Award:

  1. Consistent Academic Excellence

    • Over 20 years of service in clinical and academic gynecology.

    • Held dual leadership roles: Chief Physician and Professor at Zhejiang University.

    • Ph.D. in medicine and visiting scholarship in Australia show strong academic foundation and international exposure.

  2. Extensive Research Contributions

    • A strong record of peer-reviewed publications (2025–2019), many in indexed international journals.

    • Research impact areas: endometriosis, adenomyosis, gynecologic oncology, drug delivery, and minimally invasive surgery.

  3. Editorial and Leadership Roles

    • Editorial board member of top journals including Annals of Translational Medicine and Chinese Journal of Obstetrics and Gynecology.

    • Vice/Chairman positions in national and international medical societies, including the World Endometriosis Association.

  4. International Collaborations

    • Collaborates with leading institutions in USA (MD Anderson), France (Cochin Hospital), Brazil, and Russia, enhancing research diversity and relevance.

  5. Innovative Methods

    • Introduced novel cell culture models, biomarker-driven diagnostic tools, and nanoparticle-based drug delivery systems.

Areas for Improvement:

  1. Interdisciplinary Expansion

    • While strong in clinical research, greater integration with AI, bioinformatics, or digital diagnostics could elevate research scope.

  2. Public Health Impact

    • Scaling research from clinical environments to community-based studies or low-resource settings would increase societal impact.

  3. Global Recognition

    • While collaborations exist, active presence in global conferences, panels, or international guideline development would boost global profile.

Education:

Prof. Xinmei Zhang received her Ph.D. in Medicine from Zhejiang University between August 2009 and December 2011. She pursued advanced clinical training and research with a focus on gynecology and reproductive health. Earlier in her career, she served as a visiting scholar at Queensland University Adult Hospital, Australia, in 2003, where she gained international exposure in clinical research and practice. This experience enriched her global perspective and deepened her understanding of women’s health issues. Her rigorous academic background laid the foundation for a strong career in translational gynecology, merging laboratory discoveries with clinical application. Prof. Zhang’s education has equipped her with both theoretical knowledge and practical skills in molecular medicine, surgical gynecology, and women’s reproductive disorders. As an educator and researcher, she continues to mentor young clinicians and researchers in China and abroad, ensuring the next generation inherits both technical expertise and a strong ethical foundation.

Experience:

Prof. Xinmei Zhang has been serving as a Chief Physician at the Women’s Hospital, Zhejiang University since 2005, and was promoted to Professor at the School of Medicine in 2021. Her work encompasses clinical leadership, research coordination, and educational mentorship. As the head of the Department of Gynecology and co-lead at the Zhejiang Provincial Key Laboratory for Precision Diagnosis and Therapy of Major Gynecological Diseases, she spearheads initiatives in translational medicine. Her editorial appointments include prominent journals such as the Chinese Journal of Obstetrics and Gynecology and Annals of Translational Medicine. She is also a recognized leader in several professional organizations, including serving as Vice Chairman in multiple national and regional medical associations. Prof. Zhang has conducted multi-center clinical studies, developed advanced surgical techniques, and collaborated internationally on research projects. Her rich experience makes her a cornerstone in China’s gynecological research and healthcare innovation.

Research Focus:

Prof. Xinmei Zhang’s research centers on endometriosis, adenomyosis, and gynecologic oncology, with a strong emphasis on the molecular mechanisms, immune pathways, and targeted therapies. She investigates inflammatory chemokines (e.g., CCL2, CCR4, CCL18), epithelial-mesenchymal transition, neuroangiogenesis, and tumorigenic signaling pathways, bridging lab-based molecular research with clinical treatment strategies. Her studies explore novel biomarkers for diagnosis (e.g., ROMA Index for endometrial cancer) and innovative therapeutic models like curcumin–paclitaxel nano-delivery systems. Prof. Zhang has also pioneered methods for isolating ectopic stromal and epithelial cells to model adenomyosis, thus facilitating personalized medicine approaches. Her cross-border collaborations strengthen her work’s global relevance, especially in addressing complex conditions that impact women’s reproductive health and quality of life. With a publication record in high-impact journals, she contributes both to fundamental science and its translation into patient care. Her research is backed by strong institutional support and an extensive global academic network.

Publication Top Notes: 

CCL2/CCR4 participates in mast cell-mediated epithelial mesenchymal transition in endometriosis – Reproductive BioMedicine Online (2025)
CCL18 promotes endometriosis by increasing endometrial cell migration and neuroangiogenesis – European Journal of Histochemistry (2024)
A method for isolating and culturing ectopic epithelial and stromal cells to study human adenomyosis – Archives of Gynecology and Obstetrics (2023)
A method for isolating and culturing ectopic epithelial and stromal cells to study human adenomyosis – Preprint Version (2023)
ROMA Index Is an Effective Predictor for Advanced Endometrial Cancer before Surgery – Disease Markers (2022)
Anemia-Associated Platelets and Plasma Prothrombin Time Increase in Patients with Adenomyosis – Journal of Clinical Medicine (2022)
Long-Term Pregnancy Outcomes of Patients with Diffuse Adenomyosis after Double-Flap Adenomyomectomy – Journal of Clinical Medicine (2022)
RON Mediates Tumor‐Promoting Effects in Endometrial Adenocarcinoma – BioMed Research International (2021)
Co-Delivery of Curcumin and Paclitaxel by “Core-Shell” Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer – International Journal of Nanomedicine (2019)
Comparisons of the efficacy and recurrence of adenomyomectomy for severe uterine diffuse adenomyosis via laparotomy versus laparoscopy – Journal of Pain Research (2019)

Conclusion:

Prof. Xinmei Zhang is a highly qualified candidate for the Best Researcher Award. Her sustained contributions to women’s health, innovative clinical and molecular research, strong global collaborations, and leadership in academic medicine represent the ideal profile of a world-class researcher. Her work not only advances science but translates directly into improved patient care—an essential criterion for this award.

Sukanta Nath | Cancer Research | Distinguished Scientist Award

Dr. Sukanta Nath | Cancer Research | Distinguished Scientist Award

Dr. Sukanta Nath, Atal Bihari Vajpayee Regional Cancer Centre, India

Dr. Sukanta Nath is a dedicated Research Scientist with over 13 years of experience in molecular biology, virology, and cancer research. He currently serves at the Atal Bihari Vajpayee Regional Cancer Centre, Agartala, Tripura, where he has led several impactful studies in oral cancer patient care. Holding a Ph.D. in Biotechnology from Gauhati University, Dr. Nath has consistently demonstrated excellence in scientific inquiry, especially in clinical intervention studies. His collaborative works with clinical and academic experts have produced over 10 peer-reviewed publications in reputed journals. Dr. Nath’s research emphasizes evidence-based nursing practices, molecular diagnostics, and the improvement of post-surgical outcomes in cancer patients. Known for his commitment to translational research, Dr. Nath is playing a pivotal role in bridging molecular science with patient-centered care in North-East India. His multidimensional expertise and scholarly contributions make him a deserving candidate for recognition as a Distinguished Scientist.

Publication Profile: 

Scopus

Strengths for the Award:

  1. Extensive Research Experience:
    With over 13 years of hands-on experience in molecular biology, cancer research, and virology, Dr. Nath has a well-established research career that aligns with the award’s standards.

  2. Focused Contributions to Cancer Research:
    His work at Atal Bihari Vajpayee Regional Cancer Centre has significantly contributed to oral cancer patient management, particularly through randomized intervention studies improving postoperative recovery and mental health.

  3. High Research Output:
    He has authored or co-authored 10+ peer-reviewed publications, many of which focus on novel and under-explored aspects such as nursing intervention in cancer care—a progressive and human-centered approach.

  4. Multidisciplinary Approach:
    Dr. Nath bridges molecular diagnostics, clinical research, and public health, evident in his work on HPV molecular epidemiology and AML treatment reviews.

  5. Collaborative and Institutional Impact:
    His collaborations with clinicians, nurses, and academic institutions highlight his team-oriented and translational research vision, helping integrate academic outputs into real-world healthcare.

Areas for Improvement:

  1. International Exposure:
    Dr. Nath could enhance his academic profile with international fellowships, collaborative projects, or presentations at global conferences, which would add broader recognition and perspective to his impactful regional work.

  2. Grant Acquisition & Leadership Roles:
    Documented principal investigator roles or research funding/grant awards would strengthen his leadership credentials in scientific research.

  3. Recognition & Awards:
    While he has a commendable publication record, more national or state-level recognitions, fellowships, or memberships in professional bodies (like ICMR, DBT, etc.) would boost his candidacy for national-level honors.

Education:

Dr. Sukanta Nath’s academic foundation is rooted in the biological sciences, beginning with a B.Sc. in Botany, Zoology, and Physiology from Calcutta University (2003, First Class). He went on to complete his M.Sc. in Biotechnology from Utkal University in 2006, securing First Class (67%). His research potential culminated in a Ph.D. in Biotechnology from Gauhati University, awarded in 2018, where he specialized in molecular biology and translational biomedical science. His education reflects a progressive mastery of theoretical and applied biotechnology, allowing him to engage in complex interdisciplinary research. Despite modest early academic challenges in higher secondary and matriculation, Dr. Nath’s academic trajectory sharply ascended, reflecting perseverance and intellectual growth. His doctoral training equipped him with specialized skills in molecular diagnostics, research design, and bioanalytical tools, which now form the backbone of his professional research work in cancer and infectious disease.

Professional Experience:

Dr. Nath is presently serving as a Research Scientist at the Atal Bihari Vajpayee Regional Cancer Centre, Tripura, since April 2020, where he conducts pivotal research on postoperative outcomes and interventions in oral cancer patients. Previously, he worked as a Research Associate at the College of Fisheries, Central Agricultural University, Tripura (2018–2019), contributing to institutional-level biotech projects. In 2017–2018, he served as a Molecular Scientist and Quality Manager at Agility Diagnostics Pvt. Ltd., Delhi, a NABL-accredited molecular diagnostics lab, where he gained valuable experience in molecular testing and lab quality control. With over 13 years of interdisciplinary experience, Dr. Nath has successfully combined clinical and molecular biology expertise, making impactful contributions to oncology, diagnostics, and public health. His adaptability across academic, clinical, and industry environments illustrates his wide-ranging capabilities as a biomedical researcher and project leader.

Awards and Honors:

While specific named awards are not listed in the provided resume, Dr. Sukanta Nath’s contributions have earned peer recognition through frequent lead and co-author roles in high-impact publications. His ongoing collaboration with clinicians, epidemiologists, and nursing researchers has positioned him as a sought-after expert in cancer-related intervention studies in North-East India. He has been an instrumental figure in pioneering randomized clinical studies assessing fatigue, anxiety, and quality of life in post-surgical oral cancer patients—work that has been accepted in internationally indexed journals. His contributions to the molecular epidemiology of HPV in Indian women also reflect national relevance. The volume and scope of his work, alongside a sustained publication record, underline a distinguished career in translational cancer research. Nomination for the Distinguished Scientist Award is a well-aligned recognition of his achievements and continued potential to contribute at the national level.

Research Focus:

Dr. Nath’s primary research interest lies in molecular biology, oncology, and virology, with a strong emphasis on translational studies that impact patient care. He has led intervention-based research evaluating the role of nursing and clinical protocols in improving postoperative recovery among oral cancer patients. His work assesses anxiety, fatigue, and quality of life post-surgery using evidence-based methodologies. Dr. Nath has also contributed significantly to molecular epidemiology, particularly studying the distribution of high-risk HPV genotypes among women in North-East India. His experience in diagnostics and biotech allows him to approach clinical problems from both biomedical and molecular perspectives, making his research integrative and impactful. The focus on nursing intervention studies, rarely explored in Indian cancer centers, demonstrates his commitment to holistic cancer care. His future goals involve scaling such studies to wider patient populations and contributing to national cancer care protocols.

Publications Top Notes:

  1. 📘 Effectiveness of a supportive educational intervention on pain and physical function among patients undergone abdominal surgery: A randomized controlled trial

  2. 📗 Effectiveness of comprehensive nursing intervention on alleviating postoperative fatigue and anxiety in patients with oral cancer

  3. 📕 Molecular epidemiology and genotype distribution of genital high-risk human papillomavirus among women in North–East India

  4. 📙 Effectiveness of Nursing Interventions on Anxiety among Postoperative Oral Cancer Patients in Regional Cancer Centre, Tripura

  5. 📒 Importance of Nursing Intervention in Alleviating Post-Surgical Fatigue for Patients with Oral Cancer

  6. 📓 Does comprehensive nursing intervention improve post-surgical anxiety in patients with oral cancer?

  7. 📔 Post-Surgical Evaluation of Quality of Life in Patients with Oral Cancer: An Intervention Study from India

  8. 📚 Assessment of Fatigue and Quality of Life amongst Post-Operative Oral Cancer Patients: A Randomized Case Control Study

  9. 📙 Effect of Comprehensive Nursing Intervention on Anxiety and Quality of Life in Postoperative Patients with Oral Cancer

  10. 📗 Prognosis and Treatment in Acute Myeloid Leukemia: A Comprehensive Review

Conclusion:

Dr. Sukanta Nath has demonstrated dedicated service, innovative research, and strong scientific output in the fields of molecular biology and oncology, particularly with a patient-centric approach to oral cancer care. His work addresses a critical healthcare challenge in North-East India and proposes practical solutions backed by rigorous research methodologies.

 

Lei Shi | Tumorigenesis | Distinguished Scientist Award

Mr. Lei Shi | Tumorigenesis | Distinguished Scientist Award

Mr. Lei Shi, Lanzhou University, China

Dr. Lei Shi is a distinguished cancer biologist and molecular pathologist, currently serving as a Professor and Group Leader at the School of Public Health, Lanzhou University, China. With an international career spanning Germany, the UK, and China, Dr. Shi has significantly contributed to our understanding of long non-coding RNAs (lncRNAs), KRAS-mediated tumorigenesis, and lung cancer biology. He earned his Ph.D. from Ludwig Maximilian University of Munich, and completed postdoctoral training at the CRUK Manchester Institute, one of the world’s premier cancer research centers. His interdisciplinary research bridges cancer signaling, immunotherapy, and molecular genetics. Dr. Shi has been the recipient of multiple national and international grants and has authored numerous high-impact publications in journals such as Nature Communications, Molecular Cancer, and Cell Death & Differentiation. His research plays a pivotal role in advancing personalized cancer therapy and diagnostics, making him a strong contender for the Distinguished Scientist Award.

Publication Profile: 

Orcid

Scopus

Strengths for the Award:

  1. Extensive Expertise in Tumorigenesis
    Dr. Shi has built a deep and consistent research track record in lung cancer biology, KRAS signaling, and non-coding RNAs—critical areas in modern tumorigenesis research. His work spans oncogene-driven pathways, epigenetics, and RNA biology, which are all highly relevant to the theme of this award.

  2. Strong International Training and Collaborations
    His academic path includes a Ph.D. in Germany (LMU Munich), a postdoctoral fellowship in the UK (University of Manchester/Cancer Research UK), and leadership in China—demonstrating international impact and collaboration.

  3. Proven Research Leadership
    As a Group Leader and Professor at Lanzhou University, Dr. Shi has led grants from both national and provincial Chinese funding bodies, showcasing strong institutional leadership and research independence.

  4. High-Impact Publications
    Dr. Shi has multiple first-author and corresponding-author publications in top-tier journals like Nature Communications, Molecular Cancer, Cell Death & Differentiation, Cancer Research, and others. This indicates a sustained contribution to scientific knowledge with measurable impact.

  5. Focus on Translational Relevance
    His work on KRAS-mediated tumorigenesis, lncRNAs in cancer, microRNA regulation, and drug resistance directly contributes to potential cancer therapies and diagnostics, aligning with the translational emphasis of many distinguished awards.

  6. Mentorship and Emerging Talent Development
    Multiple publications list junior co-authors under his supervision, showing that he actively mentors young scientists and builds collaborative research teams.

Areas for Improvement:

  1. Broader Recognition in Global Awards
    While Dr. Shi has an impressive research footprint, there is limited mention of international awards, editorial roles, or keynote presentations, which are often considered markers of distinguished global leadership.

  2. Clinical Translation or Patents
    The profile would benefit from stronger clinical application indicators, such as patents, clinical trials, or biotechnology translation, to further demonstrate real-world impact.

  3. Broader Research Diversification
    Although his expertise is deep in KRAS and RNA biology, engaging with emerging areas like AI in cancer research, organoid modeling, or immune-oncology interfaces could amplify his multidisciplinary influence.

Education:

Dr. Lei Shi’s academic journey is deeply rooted in life sciences and molecular pathology. He obtained his Bachelor’s degree in Veterinary Medicine (2003–2007) from Heibei North University, China, followed by a Master’s degree (2007–2010) in Agricultural Microbiology at Huazhong Agricultural University, where he developed his early interest in pathogenic mechanisms. He then pursued his Ph.D. (Dr.rer.nat) in Molecular Pathology (2011–2014) at the Ludwig Maximilian University of Munich, Germany, under the mentorship of Prof. Dr. Heiko Hermeking. His doctoral research explored the transcriptional regulation of tumor suppressors and oncogenes. This academic progression built a solid foundation in molecular oncology, leading to a postdoctoral fellowship (2015–2021) at the Cancer Research UK Manchester Institute and Lung Cancer Centre of Excellence, UK. Dr. Shi’s diverse education has provided him with a global and translational perspective on cancer biology, strengthening his leadership in molecular oncology research today.

Professional Experience:

Dr. Lei Shi is a Professor and Group Leader (2021–present) at Lanzhou University, where he heads translational cancer biology research within the School of Public Health. Prior to this, he held a prestigious Postdoctoral Research Fellow role (2015–2021) at the Cancer Research UK Manchester Institute, affiliated with The University of Manchester. There, he conducted cutting-edge research on KRAS-driven lung cancers, drug resistance mechanisms, and RNA therapeutics. Earlier, he was a Ph.D. researcher (2011–2014) at Ludwig Maximilian University of Munich, delving into the regulatory roles of p53 and lncRNAs. His professional experience reflects a continuum of cancer research from fundamental science to translational applications. Dr. Shi’s team at Lanzhou University is now exploring new therapeutic targets for non-small cell lung cancer and virus-associated cancers. He has secured multiple prestigious national and international grants and is actively mentoring the next generation of cancer researchers in China.

Research Focus:

Dr. Lei Shi’s research centers on the molecular mechanisms of cancer development and progression, with a primary focus on long non-coding RNAs (lncRNAs), KRAS oncogene signaling, and RNA-based therapeutic strategies. His lab investigates how lncRNAs modulate gene expression, interact with microRNAs, and influence tumor microenvironment and immune response, particularly in non-small cell lung cancer (NSCLC) and virus-related malignancies. Dr. Shi is also exploring transcriptional feedback loops, including interactions between HIF1A-AS2 and MYC, to unravel how oncogenic pathways fuel metastasis. His postdoctoral work revealed KRAS-induced microRNA regulation, significantly advancing the understanding of RNA biology in cancer. Dr. Shi’s research integrates bioinformatics, functional genomics, and clinical samples to identify novel biomarkers and therapeutic targets. His contributions are paving the way for precision oncology, making a significant impact on early diagnosis, patient stratification, and drug resistance profiling in solid tumors, especially lung cancer.

Publications Top Notes: 

  1. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy – Molecular Cancer (2025)

  2. Long non-coding RNA-encoded micropeptides: functions, mechanisms and implications – Cell Death & Discovery (2024)

  3. p53-regulated lncRNAs in cancers: from proliferation and metastasis to therapy – Cancer Gene Therapy (2023)

  4. Long non-coding RNA HIF1A-As2 and MYC form a double positive feedback loop in NSCLC – Cell Death & Differentiation (2023)

  5. Long non-coding RNAs in virus-related cancers – Reviews in Medical Virology (2022)

  6. Prognostic and immunotherapeutic roles of KRAS in Pan-Cancer – Cells (2022)

  7. A KRAS-responsive long non-coding RNA controls microRNA processing – Nature Communications (2021)

  8. Diverse roles of long non-coding RNA in viral diseases – Reviews in Medical Virology (2020)

  9. Vulnerability of drug-resistant EML4-ALK lung cancer to transcriptional inhibition – EMBO Mol Med (2020)

  10. KRAS induces lung tumorigenesis through microRNAs modulation – Cell Death & Disease (2018)

  11. The immunological and prognostic landscape of TFAP4 in cancer (scRNA-seq study) – Archives of Biochemistry and Biophysics (2025)

Conclusion:

Dr. Lei Shi is highly suitable for the Distinguished Scientist Award in Tumorigenesis Research. His exceptional publication record, international training, leadership in cancer biology, and dedication to translational science make him a standout candidate. With ongoing contributions and future expansion into cross-disciplinary domains, his research trajectory is aligned with the highest standards of scientific distinction.

Jean-Marc LEMAITRE | Cellular Senescence Aging | Best Researcher Award

Dr. Jean-Marc LEMAITRE | Cellular Senescence Aging | Best Researcher Award

Dr. Jean-Marc LEMAITRE, INSERM UMR1183, France

Jean-Marc Lemaitre is a French biomedical researcher internationally renowned for his groundbreaking work on cellular reprogramming and aging reversal. Born on October 14, 1963, he is currently based at the Institute for Regenerative Medicine and Biotherapies (IRMB) in Montpellier, where he serves as co-director. His work has transformed the understanding of how aged cells can be rejuvenated, offering new hope for regenerative therapies. With a strong academic and clinical research background, Lemaitre has authored over 100 scientific articles and books on senescence, stem cells, and epigenetics. He is a board member of several scientific societies and journals, and continues to drive research at the frontier of aging science. Lemaitre is also a public science communicator and author, helping bridge cutting-edge biology with societal challenges related to aging. His passion for improving human health through innovative science places him at the forefront of biomedical research in France and globally.

Publication Profile:

Orcid

Google Scholar

Strengths for the Award:

  1. Pioneering Work in Aging Reversal
    Lemaitre was among the first scientists to show that senescent human cells can be rejuvenated, contributing significantly to cellular reprogramming and epigenetic longevity science.

  2. High-Impact Publications & Scientific Output
    Authored or co-authored over 100 scientific works, including in Nature Aging, Molecular Cell, Scientific Reports, and PNAS. His studies are cited globally in aging, regenerative medicine, and stem cell therapy.

  3. Institutional Leadership
    As Co-Director and Co-founder of IRMB, he manages a research institute with 180+ staff, positioning him as a key scientific leader in France.

  4. Scientific Recognition
    Member of scientific editorial boards and committees (e.g., Cells journal, Ligue Contre le Cancer), and board member of FSSCR, reflecting sustained leadership in the stem cell field.

  5. Translational & Interdisciplinary Impact
    His research has led to clinical insights in dermatology, osteoarthritis, and cardiology, demonstrating broad biomedical relevance beyond aging biology.

  6. Public Engagement and Science Communication
    Author of books like “Guérir la Vieillesse” and “Décider de son âge”, he bridges scientific knowledge with public interest in health and longevity.

Areas for Improvement:

  1. Expanded International Collaborations
    While Lemaitre collaborates across disciplines, further integration into global consortia or partnerships with biotech/pharma could amplify the translational value of his work.

  2. Visibility in Policy or Global Aging Initiatives
    Participation in policy advisory boards or international aging panels (e.g., WHO, UN Decade of Healthy Aging) would enhance his influence in shaping public health approaches to aging.

  3. Startups or Technology Transfer
    Commercialization of his discoveries (e.g., senescence therapies or reprogramming protocols) through startups or IP licensing would elevate his impact on innovation and real-world application.

Education:

Jean-Marc Lemaitre’s academic journey is rooted in molecular and developmental biology. He earned his DEA (Diplôme d’Études Approfondies) in Developmental Biology from Paris 6 University in 1991. His Doctorate (PhD) followed in 1995 from Paris 7 University, with research conducted at the esteemed Institut Jacques Monod in molecular and cellular biology. His early focus on the fundamental processes of cell development laid the groundwork for his future expertise in aging and regenerative medicine. In 2005, Lemaitre earned his Habilitation to Direct Research (HDR) from Montpellier University Medical School, a prestigious credential that allowed him to lead independent research projects. His educational path reflects a consistent and deep engagement with life sciences and a strong commitment to academic excellence. These milestones set the foundation for his leading role in cellular reprogramming and senescence-related research at both national and international levels.

Experience:

Jean-Marc Lemaitre has amassed over 30 years of professional experience in biomedical research, with a major focus on aging, senescence, and regenerative medicine. Since 2015, he has served as Co-Director and Cofounder of the IRMB (Institute for Regenerative Medicine and Biotherapies), which now houses over 180 researchers. His professional base is at the Saint Eloi Hospital in Montpellier, where he contributes both to translational research and clinical collaborations. Between 2014 and 2018, he held a Contrat d’Interface at CHU Montpellier, strengthening ties between research and healthcare. His pioneering work in cellular reprogramming earned international acclaim for demonstrating that senescent human cells could be rejuvenated using induced pluripotent stem cell (iPSC) technology. Lemaitre also plays leadership roles in research consortia such as the FHU REGENHAB and is an elected member of scientific committees, including the LIGUE Contre le Cancer du Septentrion. His experience is both deep and influential in shaping modern aging research.

Awards and Honors:

Jean-Marc Lemaitre has been recognized multiple times for his leadership and innovation in biomedical science. He was elected to the Scientific Committee of the LIGUE Contre le Cancer du Septentrion in 2019, reflecting his growing influence in translational medicine. In 2015, he co-founded and became Co-Director of IRMB, an institute now pivotal in stem cell and regenerative therapies. From 2014 to 2018, he was awarded a Contrat d’Interface at CHU Montpellier, enhancing integration between research and clinical practice. His work has also earned him positions on international editorial boards, including the “Cells” journal since 2020. In 2007, he co-founded and became a board member of the French Society for Stem Cell Research (FSSCR). These honors reflect not only the quality of his scientific contributions but also his dedication to mentorship, institution-building, and public engagement in science. He remains a key figure in aging and regenerative medicine globally.

Research Focus:

Jean-Marc Lemaitre’s research centers on cellular aging, senescence, and regenerative medicine. He is internationally renowned for demonstrating that aged or senescent human cells can be reprogrammed back to a pluripotent state—effectively reversing aging markers. His team has been at the forefront of identifying epigenetic mechanisms involved in aging and developing short reprogramming protocols to extend healthspan. He works extensively on senotherapeutics—interventions targeting the senescent cells that drive aging and disease—and has published seminal studies on skin aging, musculoskeletal regeneration, and systemic rejuvenation. Lemaitre is also a thought leader in developing blood-based epigenetic clocks to monitor aging and predict mortality. His integrative approach blends molecular biology, stem cell science, and translational medicine to uncover ways to slow or reverse aging processes. His work opens promising therapeutic avenues for treating age-related diseases, improving healthspan, and potentially redefining biological age through cellular reprogramming technologies.

Publications Top Notes:

  1. Disc-Derived iPSCs and Environmental Cues for Nucleus Pulposus Regeneration (Tissue Eng Part A, 2025)

  2. Blood-Based Epigenetic Clock for Intrinsic Capacity and Mortality (Nat Aging, 2025)

  3. Niacinamide and Hyaluronic Acid for Skin Aging: Clinical Correlation (Sci Rep, 2024)

  4. Décider de son âge (Book, 2024 – Allary Editions)

  5. Therapeutic Approaches Targeting Senescent Cells (Cells, 2023)

  6. Guérir la Vieillesse (Book, 2022 – Humensciences)

  7. Single Short Reprogramming Increases Healthspan (Aging, 2022)

  8. Epigenetic Mechanism Linking Early Reprogramming to Lifespan (Aging Cell, 2022)

  9. DNMT1-Driven 4D Genome Rewiring in Senescence (Molecular Cell, 2020)

  10. DNA Replication Timing as Marker in Progeroid Diseases (PNAS, 2017)

Conclusion:

Jean-Marc Lemaitre is a highly deserving candidate for the Best Researcher Award. He combines groundbreaking research in cellular aging and epigenetics with institutional leadership and public engagement. His work has transformed the understanding of biological aging, making him one of the most influential biomedical scientists in Europe in this domain. The award would not only recognize his scientific excellence but also highlight the increasing importance of healthy aging, regenerative medicine, and cellular rejuvenation in modern medicine.